Genmab A/S (NASDAQ:GMAB) Rating Reiterated by HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Genmab A/S (NASDAQ:GMAB) in a report published on Friday, Benzinga reports. The firm currently has a $50.00 price target on the stock.

Several other brokerages have also recently commented on GMAB. Royal Bank of Canada raised shares of Genmab A/S from a sector perform rating to an outperform rating in a research report on Monday, July 15th. Morgan Stanley reiterated an equal weight rating and issued a $31.00 target price on shares of Genmab A/S in a report on Wednesday. Truist Financial cut their price target on Genmab A/S from $53.00 to $50.00 and set a buy rating on the stock in a report on Monday, September 9th. BTIG Research lifted their price objective on Genmab A/S from $46.00 to $47.00 and gave the company a buy rating in a research note on Thursday, June 27th. Finally, JPMorgan Chase & Co. restated a neutral rating on shares of Genmab A/S in a research note on Tuesday, August 20th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, Genmab A/S presently has a consensus rating of Hold and a consensus target price of $45.20.

Genmab A/S Trading Up 1.5 %

GMAB stock opened at $26.90 on Friday. The business’s fifty day moving average price is $27.25 and its 200 day moving average price is $28.07. Genmab A/S has a 12-month low of $24.53 and a 12-month high of $38.80. The company has a market capitalization of $17.79 billion, a PE ratio of 22.42, a P/E/G ratio of 0.81 and a beta of 0.99.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Thursday, August 8th. The company reported $0.22 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.07). The business had revenue of $779.50 million for the quarter, compared to analysts’ expectations of $734.60 million. Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. Research analysts predict that Genmab A/S will post 1.27 EPS for the current fiscal year.

Hedge Funds Weigh In On Genmab A/S

Several hedge funds have recently added to or reduced their stakes in GMAB. Capital International Investors lifted its position in shares of Genmab A/S by 7.8% during the 1st quarter. Capital International Investors now owns 4,373,277 shares of the company’s stock worth $130,805,000 after buying an additional 315,355 shares during the last quarter. Harding Loevner LP lifted its position in Genmab A/S by 2.7% in the fourth quarter. Harding Loevner LP now owns 3,289,895 shares of the company’s stock valued at $97,569,000 after acquiring an additional 85,665 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Genmab A/S by 7.6% in the second quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock valued at $36,752,000 after acquiring an additional 103,859 shares in the last quarter. First Trust Advisors LP grew its holdings in shares of Genmab A/S by 16.0% during the fourth quarter. First Trust Advisors LP now owns 1,270,095 shares of the company’s stock worth $40,440,000 after purchasing an additional 175,292 shares during the last quarter. Finally, DDD Partners LLC acquired a new stake in shares of Genmab A/S during the second quarter worth about $8,860,000. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.